Alejandro Lopez-Rincon

Dr. Alejandro Lopez-Rincon


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
ATAlberto Tonda
Alberto Tonda
LMLucero Mendoza-Maldonado
Lucero Mendoza-Maldonado
DMDaphne G. J. C. Mulders
Daphne G. J. C. Mulders
RMRichard Molenkamp
Richard Molenkamp
AKAletta D. Kraneveld
Aletta D. Kraneveld
In this paper, deep learning is coupled with explainable artificial intelligence techniques for the discovery of representative genomic sequences in SARS-CoV-2. A convolutional neural network classifier is first trained on 553 sequences from the National Genomics Data Center repository, separating the genome of different virus strains from the Coronavirus family with 98.73% accuracy. The network’s behavior is then analyzed, to discover sequences used by the model to identify SARS-CoV-2, ultimately uncovering sequences exclusive to it. The discovered sequences are validated on samples from the National Center for Biotechnology Information and Global Initiative on Sharing All Influenza Data repositories, and are proven to be able to separate SARS-CoV-2 from different virus strains with near-perfect accuracy. Next, one of the sequences is selected to generate a primer set, and tested against other state-of-the-art primer sets, obtaining competitive results. Finally, the primer is synthesized and tested on patient samples (n = 6 previously tested positive), delivering a sensitivity similar to routine diagnostic methods, and 100% specificity. The proposed methodology has a substantial added value over existing methods, as it is able to both automatically identify promising primer sets for a virus from a limited amount of data, and deliver effective results in a minimal amount of time. Considering the possibility of future pandemics, these characteristics are invaluable to promptly create specific detection methods for diagnostics.

3 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
LMLucero Mendoza-Maldonado
Lucero Mendoza-Maldonado
MMMarlet Martinez
Marlet Martinez
ASAlexander Schönhuth
Alexander Schönhuth
AKAletta Desiree Kraneveld
Aletta Desiree Kraneveld
ATAlberto Tonda
Alberto Tonda
Circulating microRNAs (miRNA) are small noncoding RNA molecules that can be detected in bodily fluids without the need for major invasive procedures on patients. miRNAs have shown great promise as biomarkers for tumors to both assess their presence and to predict their type and subtype. Recently, thanks to the availability of miRNAs datasets, machine learning techniques have been successfully applied to tumor classification. The results, however, are difficult to assess and interpret by medical experts because the algorithms exploit information from thousands of miRNAs. In this work, we propose a novel technique that aims at reducing the necessary information to the smallest possible set of circulating miRNAs. The dimensionality reduction achieved reflects a very important first step in a potential, clinically actionable, circulating miRNA-based precision medicine pipeline. While it is currently under discussion whether this first step can be taken, we demonstrate here that it is possible to perform classification tasks by exploiting a recursive feature elimination procedure that integrates a heterogeneous ensemble of high-quality, state-of-the-art classifiers on circulating miRNAs. Heterogeneous ensembles can compensate inherent biases of classifiers by using different classification algorithms. Selecting features then further eliminates biases emerging from using data from different studies or batches, yielding more robust and reliable outcomes. The proposed approach is first tested on a tumor classification problem in order to separate 10 different types of cancer, with samples collected over 10 different clinical trials, and later is assessed on a cancer subtype classification task, with the aim to distinguish triple negative breast cancer from other subtypes of breast cancer. Overall, the presented methodology proves to be effective and compares favorably to other state-of-the-art feature selection methods.

18 September 2019 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
MMMarlet Martinez
Marlet Martinez
GMGustavo Ulises Martinez-Ruiz
Gustavo Ulises Martinez-Ruiz
ASAlexander Schönhuth
Alexander Schönhuth
ATAlberto Tonda
Alberto Tonda
Background: MicroRNAs (miRNAs) are noncoding RNA molecules heavily involved in human tumors, in which few of them circulating the human body. Finding a tumor-associated signature of miRNA, that is, the minimum miRNA entities to be measured for discriminating both different types of cancer and normal tissues, is of utmost importance. Feature selection techniques applied in machine learning can help however they often provide naive or biased results.Results: An ensemble feature selection strategy for miRNA signatures is proposed. miRNAs are chosen based on consensus on feature relevance from high-accuracy classifiers of different typologies. This methodology aims to identify signatures that are considerably more robust and reliable when used in clinically relevant prediction tasks. Using the proposed method, a 100-miRNA signature is identified in a dataset of 8023 samples, extracted from TCGA. When running eight-state-of-the-art classifiers along with the 100-miRNA signature against the original 1046 features, it could be detected that global accuracy differs only by 1.4%. Importantly, this 100-miRNA signature is sufficient to distinguish between tumor and normal tissues. The approach is then compared against other feature selection methods, such as UFS, RFE, EN, LASSO, Genetic Algorithms, and EFS-CLA. The proposed approach provides better accuracy when tested on a 10-fold cross-validation with different classifiers and it is applied to several GEO datasets across different platforms with some classifiers showing more than 90% classification accuracy, which proves its cross-platform applicability.Conclusions: The 100-miRNA signature is sufficiently stable to provide almost the same classification accuracy as the complete TCGA dataset, and it is further validated on several GEO datasets, across different types of cancer and platforms. Furthermore, a bibliographic analysis confirms that 77 out of the 100 miRNAs in the signature appear in lists of circulating miRNAs used in cancer studies, in stem-loop or mature-sequence form. The remaining 23 miRNAs offer potentially promising avenues for future research.

1 April 2018 in Applied Soft Computing
Verified
Journal Article
Closed access
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
ATAlberto Tonda
Alberto Tonda
MEMohamed Elati
Mohamed Elati
OSOlivier Schwander
Olivier Schwander
BPBenjamin Piwowarski
Benjamin Piwowarski
PGPatrick Gallinari
Patrick Gallinari

1 February 2019
Verified
Conference Paper
Closed access
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
The detection of human emotions from facial expressions is crucial for social interaction. Therefore, several systems of behavioral computing in robotics try to recognize human emotion from images and video, but most of them are trained to classify emotions in adults only. Using the standard of 6 basic emotions: sadness, happiness, surprise, anger, disgust, and fear, we try to classify the facial expressions using the NAO robot in children. In this study, we make the comparison between the AFFDEX SDK, and a Convolution Neural Network (CNN) with Viola-Jones trained with the AffectNet dataset, and tuned with the NIMH-ChEF dataset using transfer learning to classify facial expressions in children. Then, we test our system comparing the CNN and the AFFDEX SDK for classification in the Child Affective Facial Expression (CAFE) dataset. Finally, we compare both systems using the NAO robot in a subset of the AM-FED and EmoReact datasets.

14 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
ATAlberto Tonda
Alberto Tonda
LMLucero Mendoza-Maldonado
Lucero Mendoza-Maldonado
DMDaphne G.J.C. Mulders
Daphne G.J.C. Mulders
RMRichard Molenkamp
Richard Molenkamp
AKAletta Desiree Kraneveld
Aletta Desiree Kraneveld
In this paper, deep learning is coupled with explainable artificial intelligence techniques for the discovery of representative genomic sequences in SARS-CoV-2. A convolutional neural network classifier is first trained on 553 sequences from available repositories, separating the genome of different virus strains from the Coronavirus family with considerable accuracy. The network’s behavior is then analyzed, to discover sequences used by the model to identify SARS-CoV-2, ultimately uncovering sequences exclusive to it. The discovered sequences are first validated on samples from other repositories, and proven able to separate SARS-CoV-2 from different virus strains with near-perfect accuracy. Next, one of the sequences is selected to generate a primer set, and tested against other state-of-the-art primer sets on existing datasets, obtaining competitive results. Finally, the primer is synthesized and tested on patient samples (n=6 previously tested positive), delivering a sensibility similar to routine diagnostic methods, and 100% specificity. In this paper, deep learning is coupled with explainable artificial intelligence techniques for the discovery of representative genomic sequences in SARS-CoV-2. A convolutional neural network classifier is first trained on 553 sequences from NGDC, separating the genome of different virus strains from the Coronavirus family with accuracy 98.73%. The network’s behavior is then analyzed, to discover sequences used by the model to identify SARS-CoV-2, ultimately uncovering sequences exclusive to it. The discovered sequences are validated on samples from NCBI and GISAID, and proven able to separate SARS-CoV-2 from different virus strains with near-perfect accuracy. Next, one of the sequences is selected to generate a primer set, and tested against other state-of-the-art primer sets, obtaining competitive results. Finally, the primer is synthesized and tested on patient samples (n=6 previously tested positive), delivering a sensibility similar to routine diagnostic methods, and 100% specificity. The proposed methodology has a substantial added value over existing methods, as it is able to both identify promising primer sets for a virus from a limited amount of data, and deliver effective results in a minimal amount of time. Considering the possibility of future pandemics, these characteristics are invaluable to promptly create specific detection methods for diagnostics.